Key facts
- This page summarizes Robert William Georgantas III's Form 4 filing for BIODESIX INC (BDSX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 21 Nov 2022, 17:02.
Robert William Georgantas III - 21 Nov 2022 Form 4 Insider Report for BIODESIX INC (BDSX)
- Reporting relationship
- Chief Scientific Officer
- Issuer ticker
- BDSX
- Reported as of
- 21 Nov 2022
- Net transaction value
- +$13,800
- SEC form
- 4
- Accepted by SEC
- 21 Nov 2022, 17:02:34 UTC
- Prior SEC filing
- 10 Nov 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Robin H. Cowie as Attorney-in-Fact for Robert Georgantas III
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Robert William Georgantas III filed Form 4 for BIODESIX INC (BDSX) on 21 Nov 2022.
Change
- Previous filing in this sequence was filed on 10 Nov 2022.
- Current net transaction value: +$13,800.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BDSX
transaction
Common Stock
Award
- Transaction value
- $13,800
- Shares
- +12,000
- Change %
- +46%
- Price
- $1.15
- Shares after
- 38,114
- Date
- 21 Nov 2022
- Ownership
- Direct
BDSX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 100
- Date
- 21 Nov 2022
- Ownership
- By UGMA Account
* marks a reported price that did not pass the local price check.